5.41
-0.04 (-0.64%)
| Previous Close | 5.44 |
| Open | 5.38 |
| Volume | 560,790 |
| Avg. Volume (3M) | 1,179,146 |
| Market Cap | 1,216,984,448 |
| Price / Earnings (TTM) | 5.81 |
| Price / Earnings (Forward) | 5.24 |
| Price / Sales | 2.02 |
| Price / Book | 1.63 |
| 52 Weeks Range | |
| Earnings Date | 13 Aug 2025 - 18 Aug 2025 |
| Profit Margin | 34.50% |
| Operating Margin (TTM) | -6,128.33% |
| Diluted EPS (TTM) | 0.930 |
| Quarterly Revenue Growth (YOY) | -92.80% |
| Total Debt/Equity (MRQ) | 5.78% |
| Current Ratio (MRQ) | 7.65 |
| Operating Cash Flow (TTM) | 157.03 M |
| Levered Free Cash Flow (TTM) | 92.39 M |
| Return on Assets (TTM) | 19.92% |
| Return on Equity (TTM) | 33.04% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | CureVac N.V. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 4.0 |
| Average | -0.63 |
|
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company’s other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 57.37% |
| % Held by Institutions | 4.70% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Gates Foundation | 30 Sep 2024 | 1,568,866 |
| Gsa Capital Partners Llp | 31 Mar 2025 | 307,941 |
| Goldman Sachs Group Inc | 31 Mar 2025 | 267,404 |
| Deutsche Bank Ag\ | 31 Mar 2025 | 230,813 |
| Bnp Paribas Financial Markets | 31 Mar 2025 | 224,523 |
| Swiss National Bank | 31 Mar 2025 | 198,547 |
| Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt | 31 Mar 2025 | 173,084 |
| Freestone Capital Holdings, Llc | 31 Mar 2025 | 144,073 |
| Legal & General Group Plc | 31 Mar 2025 | 114,839 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 10.00 (JMP Securities, 85.01%) | Buy |
| Median | 5.50 (1.76%) | |
| Low | 5.00 (Jefferies, -7.49%) | Hold |
| Average | 6.83 (26.36%) | |
| Total | 1 Buy, 2 Hold | |
| Avg. Price @ Call | 5.14 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| UBS | 26 Jun 2025 | 5.50 (1.76%) | Hold | 5.41 |
| 30 Apr 2025 | 12.00 (122.02%) | Buy | 3.55 | |
| Jefferies | 13 Jun 2025 | 5.00 (-7.49%) | Hold | 5.57 |
| JMP Securities | 28 May 2025 | 10.00 (85.01%) | Buy | 4.44 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 24 Jun 2025 | Announcement | CureVac Announces Voting Results of General Meeting |
| 20 May 2025 | Announcement | CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates |
| 15 May 2025 | Announcement | CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE |
| 10 Apr 2025 | Announcement | CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update |
| 08 Apr 2025 | Announcement | CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025 |
| 07 Apr 2025 | Announcement | CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer |
| 27 Mar 2025 | Announcement | CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |